(S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine CAS:132335-44-5

The synthesis and study of (S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine have garnered interest in the pharmaceutical and chemical research fields. The enantioselective synthesis of this compound is challenging but crucial to access pure enantiomers for studying their pharmacological activities. Researchers have developed various synthetic routes utilizing chiral resolving agents or asymmetric catalysts to obtain the desired enantiomer. Studies have shown that the (S)-enantiomer of beta-blockers like (S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine may exhibit higher affinity and selectivity towards beta-adrenergic receptors compared to the (R)-enantiomer, making it a promising candidate for further drug development. Further research on the pharmacological properties and therapeutic potential of (S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine is warranted to explore its efficacy and safety profile in clinical settings. Understanding the structure-activity relationship of this compound and its interactions with beta receptors can lead to the development of novel beta-blockers with improved therapeutic outcomes and reduced side effects. Overall, (S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine represents a valuable chemical entity in the realm of pharmaceutical research, offering insights into the design and development of cardiovascular drugs with enhanced pharmacological properties.